Peripheral Expression of CXCL10 Gene in Chronic Hepatitis C Patients Treated with Sofosbuvir, Daclatasvir, and Ribavirin

被引:5
|
作者
Afzal, Maira [1 ]
Ali, Amjad [2 ]
Sheikh, Nadeem [3 ]
Rafique, Shazia [4 ]
Idrees, Muhammad [4 ]
机构
[1] Univ Punjab, Ctr Appl Mol Biol CAMB, Mol Virol Lab, Lahore, Pakistan
[2] Hazara Univ Mansehra, Dept Genet, Khyber Pakhtunkhwa 21310, Pakistan
[3] Univ Punjab, Dept Zool, Lahore, Pakistan
[4] Univ Punjab, Ctr Excellence Mol Biol CEMB, Div Mol Virol, Lahore, Pakistan
来源
关键词
CXCL10; expression; HCV; DAAs; patients; HEPATOCELLULAR-CARCINOMA; ANTIVIRAL THERAPY; VIRUS-INFECTION; PEGINTERFERON ALPHA-2A; PEGYLATED INTERFERON; TREATMENT-NAIVE; PLUS RIBAVIRIN; VIRAL RESPONSE; IP-10; CXCL10; GENOTYPE;
D O I
10.1089/jir.2019.0185
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hepatitis C virus (HCV) causes persistent infection and invades host's innate and adaptive immune systems. During the eradication of this pathogen, the components of immune system may cause bystander damage to host, which might be even worse than the viral pathogenesis. Thus, the therapy should not only eliminate primary virus infection but also improve the inflammatory immune responses. The breakthrough of interferon free direct acting antiviral (DAA) drugs has provided the opportunity to unravel the association of HCV with immune response. This study aimed to examine the expression level of C-X-C motif chemokine ligand 10 (CXCL10) in the Peripheral blood mononuclear cells (PBMCs) of HCV infected patients treated with DAAs + Ribavirin. In this study we analyzed the expression levels ofCXCL10mRNA in the 90 chronic HCV patients using quantitative PCR (qPCR) prior, after, and during therapy with sofosbuvir/ribavirin (SOF+RBV) and sofosbuvir/daclatasvir/ribavirin (SOF+DCV+RBV), and further, the results were analyzed relative to treatment response. Significantly elevatedCXCL10mRNA was seen in naive patients having higher viral load (P = 0.005) and those suffering from hepatocellular carcinoma (P = 0.006). HCV patients had remarkable decline inCXCL10level after 4, 12, and 24 weeks of therapy with DAAs. An approximate one-fold decrease was observed in patients who attained sustained virological response compared to untreated patients (P< 0.0001). Comparing the 2 regimens, the reduction in peripheralCXCL10expression was more pronounced in patients undergoing SOF+DCV+RBV therapy. The current study implicitly shows the role ofCXCL10as an indicator of disruption of host-virus equilibrium and consequent pathogenesis of HCV during successful antiviral therapy. Furthermore, the drop inCXCL10level after HCV viral clearance might reflect the DAA-induced alleviation in the extrahepatic manifestation of this infection.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [31] HIGH SUCCESS RATES FOR THE USE OF SOFOSBUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR plus RIBAVIRIN, AND SOFOSBUVIR/SIMEPREVIR/DACLATASVIR plus RIBAVIRIN IN RETREATMENT OF CHRONIC HEPATITIS C AFTER UNSUCCESSFUL SOFOSBUVIR/DACLATASVIR THERAPY: A REAL-LIFE EXPERIENCE
    Said, Ebada M.
    Abdulaziz, Badawy
    Emadeldeen, Mohammed
    El Kassas, Mohamed
    HEPATOLOGY, 2019, 70 : 943A - 944A
  • [32] Full-dose sofosbuvir and daclatasvir for chronic hepatitis C infection in haemodialysis patients
    Gevers, T. J. G.
    Burger, D.
    Schipper-Reintjes, E.
    Kooistra, M. P.
    Richter, C.
    NETHERLANDS JOURNAL OF MEDICINE, 2016, 74 (05): : 225 - 227
  • [33] Treatment Outcomes for Patients Undergoing Hemodialysis with Chronic Hepatitis C on the Sofosbuvir and Daclatasvir Regimen
    Butt, Nazish
    Abbasi, Amanullah
    Khan, M. Ali
    Ali, Muhammad
    Mahesar, Ghulam B.
    Haleem, Farhan
    Manan, Abdul
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (09)
  • [34] Daclatasvir plus Sofosbuvir with or without ribavirin in patients with chronic Hepatitis C genotype 3a in Pakistani population - A real world experience
    Butt, Zamir
    Shah, Syed Muhammad Ali
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (02) : 409 - 413
  • [35] CXCL10 GENE POLYMORPHISM PREDICTS RAPID VIROLOGIC RESPONSE TO PEGYLATED INTERFERON/RIBAVIRIN COMBINATION THERAPY IN ASIAN PATIENTS WITH DIFFICULT-TO-TREAT CHRONIC HEPATITIS C GENOTYPE
    Thanapirom, K.
    Suksawatamnuay, S.
    Tangkijvanich, P.
    Treeprasertsuk, S.
    Poovorawan, Y.
    Akkarathamrongsin, S.
    Komolmit, P.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S149 - S149
  • [36] Protein expression and gene polymorphism of CXCL10 in patients with colorectal cancer
    Dimberg, Jan
    Skarstedt, Marita
    Lofgren, Sture
    Zar, Niklas
    Matussek, Andreas
    BIOMEDICAL REPORTS, 2014, 2 (03) : 340 - 343
  • [37] Estimating the cost-effectiveness of daclatasvir plus sofosbuvir versus sofosbuvir plus ribavirin for patients with genotype 3 hepatitis C virus
    McEwan, Phil
    Webster, Samantha
    Ward, Thomas
    Brenner, Michael
    Kalsekar, Anupama
    Yuan, Yong
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2017, 15
  • [38] The Efficacy of 12 Weeks of Sofosbuvir, Daclatasvir, and Ribavirin in Treating Hepatitis C Patients with Cirrhosis, Genotypes 1 and 3
    Merat, Shahin
    Sharifi, Amir Houshang
    Haj-Sheykholeslami, Arghavan
    Poustchi, Hossein
    Fattahi, Babak
    Nateghi-Baygi, Alireza
    Alavian, Seyed Moayed
    Malekzadeh, Reza
    HEPATITIS MONTHLY, 2017, 17 (01) : 1 - 4
  • [39] Morbidity and mortality during hepatitis C treatment using sofosbuvir and daclatasvir with or without ribavirin, in a cohort of Egyptian patients
    Elsadek, Hany M.
    Abdelbaser, Elsayed S.
    Emara, Mohamed H.
    Soliman, Hanan H.
    Farag, Alaa A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2020, 32 (08) : 1046 - 1053
  • [40] Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4
    El-Khayat, H.
    Fouad, Y.
    Mohamed, H. I.
    El-Amin, H.
    Kamal, E. M.
    Maher, M.
    Risk, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) : 674 - 679